Nebenwirkungen · Degarelix Accord
Degarelix Accord 80 mg powder and solvent for solution for injection Degarelix Accord 120 mg powder and solvent for solution for injection · Abschnitt 4.8 · PDF-Seite 5
HOS-151011 · Präparat HOS-100434
The most commonly observed adverse reactions during degarelix therapy in the confirmatory phase III study (N=409) were due to the expected physiological effects of testosterone suppression, including hot flushes and weight increase (reported in 25% and 7%, respectively, of patients receiving treatment for one year), or injection site adverse reactions. Transient chills, fever or influenza like illness were reported to occur hours after dosing (in 3%, 2% and 1% of patients, respectively).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-05T16:20:00Z · SHA-256 8d97d2cffef5c790f42b9d13857a0d8bd192f47ade9e728fdd1dd96085b54fbd · Passage 534c537d0f82c5498a1494a13e1f70ff70531608bffb7d5794d9f6219fb5b828 · Zeichen 31–523 im Abschnitt